Relationship between chromosomal aberrations and gene expressions in the p53 pathway in chronic lymphocytic leukemia

n	Sex-Age	Prognosis	Rai Stage	Binet Stage	FISH Results				(WBC 10⁹/L)	Hb (g/dL)	Platelet (10⁹/L)
					del(13q)	del(17p)	+12	Normala
1	F-75	bad	1	B	[–]	[+]	[–]	[–]	12.6	12.7	166.0
2	M-71	good	0	A	[–]	[–]	[–]	[+]	23.0	12.0	203.0
3	M-57	good	0	A	[–]	[–]	[–]	[+]	24.8	15.1	262.0
4	M-56	good	3	A	[–]	[–]	[–]	[+]	71.4	13.2	49.0
5	F-59	bad	2	B	[–]	[+]	[–]	[–]	7.9	10.9	284.0
6	F-74	bad	2	B	[–]	[+]	[–]	[–]	108.6	10.3	190.0
7	F-63	bad	2	A	[–]	[+]	[–]	[–]	35.4	13.4	185.0
8	M-80	bad	2	A	[–]	[+]	[–]	[–]	3.6	12.9	104.0
9	F-62	bad	0	A	[–]	[–]	[+]	[–]	190.2	12.0	192.0
10	M-67	bad	2	A	[–]	[–]	[+]	[–]	142.6	11.6	81.0
11	F-65	bad	0	A	[–]	[–]	[+]	[–]	5.2	12.1	144.0
12	F-74	bad	2	A	[–]	[–]	[+]	[–]	179.7	11.9	321.0
13	F-86	bad	3	A	[–]	[–]	[+]	[–]	213.0	8.6	113.0
14	M-60	good	3	A	[–]	[–]	[–]	[+]	51.7	9.4	137.0
15	M-46	good	2	A	[–]	[–]	[–]	[+]	15.0	14.4	184.0
16	M-54	good	0	A	[–]	[–]	[–]	[+]	41.9	13.8	352.0
17	F-61	good	1	A	[–]	[–]	[–]	[+]	11.8	12.1	148.0
18	F-67	good	0	A	[–]	[–]	[–]	[+]	195.3	10.8	188.0
19	F-53	good	2	B	[–]	[–]	[–]	[+]	39.8	11.4	135.0
20	M-67	good	0	A	[+]	[–]	[–]	[–]	74.6	12.4	183.0
21	M-62	good	2	A	[+]	[–]	[–]	[–]	121.4	14.5	294.0
22	M-68	good	0	A	[+]	[–]	[–]	[–]	37.7	13.9	197.0
23	F-46	good	1	A	[+]	[–]	[–]	[–]	59.4	12.3	91.0
24	M-58	good	2	B	[+]	[–]	[–]	[–]	201.4	11.1	101.0
25	M-66	good	0	A	[+]	[–]	[–]	[–]	43.9	12.3	88.0
26	M-61	good	4	C	[+]	[–]	[–]	[–]	110.0	13.9	39.0
27	M-51	good	2	A	[+]	[–]	[–]	[–]	98.5	14.3	250.0
28	F-78	good	3	B	[+]	[–]	[–]	[–]	13.7	11.0	324.0
29	F-63	good	0	A	[+]	[–]	[–]	[–]	113.3	11.5	178.0
30	M-64	good	0	A	[+]	[–]	[–]	[–]	432.0	15.3	206.0

FISH: fluorescence in situ hybridization; WBC: white blood cell count; Hb: hemoglobin.

a Non-del(13q), del(17p), +12.

Table 2

The mean difference values of the patient and control group according to average ᐃCt and fold change.

Gene	Average Ct		Average ᐃCt		2^-ᐃCt		Fold Change		p Value	Fold Regulation
	CLL	Control	CLL	Control	CLL	Control	CLL/ Control	95% CI		CLL/ Control
APAF1	26.57	25.28	7.72	7.54	0.004695	0.005368	0.87	0.78-0.96	0.072729	-1.14
*ATM*	27.85	27.91	9.01	10.17	0.001936	0.000869	2.23	1.67-2.79	<0.001	2.23
*ATR*	29.00	29.41	10.17	11.67	0.000871	0.000307	2.83	2.23-3.43	<0.001	2.83
BAX	25.61	25.87	6.78	8.13	0.009116	0.003578	2.55	2.15-2.95	<0.001	2.55
*CASP9*	27.35	27.58	8.52	9.84	0.002723	0.001091	2.50	2.06-2.94	<0.001	2.50
*CDK4*	26.92	27.96	8.09	10.22	0.003672	0.000839	4.38	3.20-5.56	<0.001	4.38
CDKN1A	27.59	26.82	8.75	9.08	0.002315	0.001852	1.25	0.97-1.53	0.066	1.25
*CDKN2A*	30.50	32.77	11.67	15.02	0.000307	0.000030	10.22	7.14-13.3	<0.001	10.22
*CHEK1*	31.37	31.58	12.54	13.83	0.000168	0.000068	2.45	1.98-2.92	<0.001	2.45
*CHEK2*	29.45	30.42	10.62	12.68	0.000638	0.000152	4.18	3.02-5.34	<0.001	4.18
E2F1	31.44	30.88	12.60	13.14	0.000161	0.000111	1.45	1.04-1.86	0.012741	1.45
*E2F3*	28.88	27.09	10.05	9.34	0.000944	0.001541	0.61	0.53-0.69	<0.001	-1.63
GADD45A	31.94	31.14	13.10	13.39	0.000114	0.000093	1.22	0.90-1.54	0.121	1.22
*MCL1*	23.34	21.85	4.51	4.11	0.043950	0.057965	0.76	0.66-0.86	<0.001	-1.32
*MDM2*	25.77	25.60	6.93	7.86	0.008184	0.004312	1.90	1.56-2.24	<0.001	1.90
*MDM4*	27.43	28.00	8.60	10.26	0.002577	0.000818	3.15	2.32-3.998	<0.001	3.15
*PCNA*	25.75	26.36	6.92	8.62	0.008266	0.002545	3.25	2.64-3.86	<0.001	3.25
PTEN	25.53	24.05	6.50	6.31	0.011036	0.012615	0.87	0.78-0.96	0.062542	-1.14
*RB1*	26.51	27.04	7.67	9.29	0.004894	0.001595	3.07	2.40-3.74	<0.001	3.07
*P53*	25.76	26.32	6.92	8.58	0.008229	0.002619	3.14	2.47-3.81	<0.001	3.14
PTX3	32.50	30.53	13.67	12.79	0.000077	0.000141	0.54	0.37-0.71	0.006057	-1.84
*BCL2*	25.94	27.94	7.11	10.20	0.007231	0.000850	8.5'	5.46-11.56	<0.001	8.51

[i] CLL: chronic lymphocytic leukemia.

Scatterplot comparing the normalized expression of genes between the CLL patients and healthy controls. Genes involved in CLL cell cycle and cell growth, proliferation and differentiation and apoptosis are shown. The central line indicates unchanged gene expression. Red dots represent genes with a fold regulation of >2.

Illustration of interactions between the 18 differentially-expressed genes in CLL patients (String v10, confidence view).

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/bjmg-2020-0007 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160

Journal RSS Feed

Language: English

Page range: 15 - 24

Published on: Aug 26, 2020

Published by: Macedonian Academy of Sciences and Arts

In partnership with: Paradigm Publishing Services

Keywords:

Chronic lymphocytic leukemia (CLL),

gene expression,

p53 Pathway,

Prognosis,

RT² Profiler PCR (polymerase chain reaction)Array

Related subjects:

Medicine,

Basic medical science,

Basic medical science, other

© 2020 G Öztan, M Aktan, S Palanduz, H İşsever, S Öztürk, E Nikerel, A Uçur, G Bağatir, A Bayrak, K Çefle, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 23 (2020): Issue 1 (June 2020)

Relationship between chromosomal aberrations and gene expressions in the p53 pathway in chronic lymphocytic leukemia

Figures & Tables

Table 1

Table 2

Figure 1

Figure 2

Paradigm

My account